Murat Dursun

Murat Dursun

Auto-generated profile, based on publicly available information

Murat Dursun

Faculty of Medicine Department of Urology Section of Andrology Istanbul University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2016 in The Kaohsiung Journal of Medical Sciences
Verified
Journal Article
Open access
MDMurat Dursun
Murat Dursun
HBHuseyin Besiroglu
Huseyin Besiroglu
AOAlper Otunctemur
Alper Otunctemur
EOEmin Ozbek
Emin Ozbek
Over the past decade, it has been suggested that erectile dysfunction (ED) is an early indicator of cardiovascular disease. In a recent study, a new index, termed as cardiometabolic index (CMI), was defined and measured as the product of triglyceride (TG)/high‐density lipoprotein‐cholesterol (HDL‐C) ratio and waist‐to‐height ratio, which are good predictors of coronary artery disease and main components of metabolic syndrome (MetS). All components of the CMI are also included in MetS criteria. Thus, we decided to evaluate the correlation between CMI, including the criteria of MetS, and ED. A total of 95 men with ED (ED group) and 82 healthy men (control group) were included in the study. Sexual functions were evaluated using the International Index of Erectile Function‐5 items scale. CMI was measured as the product of waist‐to‐height ratio and TG/HDL‐C ratio. Mean CMI level was 2.33 ± 0.11 in the study group and 1.14 ± 0.076 in the control group. CMI levels were significantly higher in the ED group ( p < 0.001). Because of the simplicity of measuring waist circumference, height measurement, and TG and HDL levels, CMI is an easily applicable index for evaluating cardiovascular dysfunction. ED is thought to be a precursor sign for vascular disease and a potential marker for atherosclerosis, endothelial dysfunction, and cardiovascular disease. In this context, CMI can be a useful index for the evaluation and calculation of ED risk, which was used for evaluation of cardiometabolic risk.

14 September 2014 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
MDMurat Dursun
Murat Dursun
AOAlper Otunctemur
Alper Otunctemur
EOEmin Ozbek
Emin Ozbek
SSSuleyman Sahin
Suleyman Sahin
HBHuseyin Besiroglu
Huseyin Besiroglu
IKIsmail Koklu
Ismail Koklu

22 November 2017 in The Aging Male
Verified
Journal Article
Closed access
MDMurat Dursun
Murat Dursun
HBHuseyin Besiroglu
Huseyin Besiroglu
SCSuleyman Sami Cakir
Suleyman Sami Cakir
AOAlper Otunctemur
Alper Otunctemur
EOEmin Ozbek
Emin Ozbek
Objective: Visceral adipose index (VAI) is a novel parameter for the evaluation of visceral obesity. As we know that obesity is a risk factor for erectile dysfunction (ED). So, in this study, we compared the VAI levels between the men with ED and without ED. Materials and method: A total of 177 men were included in the study. Ninety-five men with ED and 82 men without ED (control). All men were evaluated for ED by Index of Erectile Function-5 items (IIEF-5). VAI levels were calculated using body mass index, high density lipoprotein and tryglyceride levels. Results: Mean age was 53.5 (38–69) in men who have ED and 53.1 (34–69) in control. The men with ED had higher body mass index (BMI), triglyceride (TG) levels, higher waist circumference (WC) and lower high-density lipoprotein-cholesterol (HDL-C) levels. Mean VAI level was 5.18 ± 2.50 in study group and 3.47 ± 1.76 in control goup, respectively. VAI levels were statistically higher in men with ED (p < .001). Discussion: The simplicity of WC and BMI measurement and TG and HDL assessment, make VAI an easily applicable index for the evaluation of visceral fat dysfunction. VAI can be useful index for the evaluation and calculation of erectile dysfunction risk.

Verified
Journal Article
Open access
PDF file
MDMurat Dursun
Murat Dursun
EOEmin Ozbek
Emin Ozbek
AOAlper Otunctemur
Alper Otunctemur
SSSuleyman Sahin
Suleyman Sahin
SCSuleyman Sami Cakir
Suleyman Sami Cakir
Aim of the study: We compared stone size, localization, complaint at the time of applying, comorbidity, treatment and complications between older (60 years of age and older) and younger patients with urolithiasis (59 years of age and younger). Materials and Methods: We retrospectively reviewed the records of 950 consecutive patients who presented to our clinic and underwent surgery for urolithiasis from January 2007 to March 2012. The patients were divided into two groups: patients ≥ 60 years an patients < 60 years. Results: There were 174 men and 61 women in elderly group, 528 men and 187 women in younger group. Ureteral stones were found more often in the younger group compared to elderly patients (p < 0.05). Conversely, bladder stone was more frequent in the elderly group. In the elderly group comorbidities are more frequent (diabetes mellitus, hypertension, ischemic heart disease, congestive heart disease, osteoarthritis and chronic obstructive lung). Patients ≥ 60 years significantly had larger kidney and bladder stones compared the younger, but ureteral stone sizes were not statistically different between the two groups. Older patients had a higher postoperative complication rate than younger patients (16% versus 3%, p < 0.05) although postoperative complications (e.g. urinary retention, cardiac dysrythmia, fever, constipation) were not serious and resolved with medical treatment. The average length of stay in hospital was longer in the elderly group, but the difference was not statistically significant. Conclusions: Elderly patients with urolithiasis usually have larger and more complex stone disease, more comorbidities and atypical presentation.

31 December 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
EOEmin Ozbek
Emin Ozbek
AOAlper Otunctemur
Alper Otunctemur
SSSuleyman Sahin
Suleyman Sahin
MDMurat Dursun
Murat Dursun
HBHuseyin Besiroglu
Huseyin Besiroglu
MBMuammer Bozkurt
Muammer Bozkurt
Background: Metabolic syndrome (MetS) is a multifactorial disease characterized by impaired glucose tolerance/diabetes, obesity, high triglyceride levels, low HDL levels, and hypertension. In this study we evaluate the relationship between tumor size and grade, and presence of the metabolic syndrome in patients with renal cell carcinoma. Materials and Methods: Between 2007-2013, radical nephrectomy was performed for 310 patients with renal tumors in our clinic and those with pathology reported renal cell carcinoma were enrolled and divided into two groups, with and without metabolic syndrome diagnosed on the basis of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria. The relationship between tumor size and grade of the two groups (Fuhrman nuclear degree) was evaluated statistically. Results: The metabolic syndrome was found in 70 patients, with a mean age of 65.5 (40-87), as compared to 58.8 (31-84) years in the non-metabolic syndrome group. Tumor size over 7 cm was found in 54% and 33%, respectively, and tumor grade over Fuhrman 3 in 56% and 32% of patients. Patients with metabolic syndrome had significantly higher tumor size and grade (p<0.05). In the presence of hypertension, diabetes and high triglyceride levels, significant assocations were again observed (p0.05). Conclusions: Renal cancer is more aggressive in patients with metabolic syndrome. Lifestyle and risk factors were revealed to be significant influences in renal cancer patients.

1 February 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
EOEmin Ozbek
Emin Ozbek
AOAlper Otunctemur
Alper Otunctemur
MDMurat Dursun
Murat Dursun
IKIsmail Koklu
Ismail Koklu
SSSuleyman Sahin
Suleyman Sahin
MBMuammer Bozkurt
Muammer Bozkurt
Purpose: To compare histopathologic findings of patients who underwent transurethral resection of a bladder tumor (TUR-B) between groups with and without the metabolic syndrome. Materials and Methods: We retrospectively analyzed data of 535 patients who underwent TUR-B in our department between October 2005 and March 2011. All patients had primary urethelial cell carcinoma (UCB). Histologic stage, grade, the presence of hypertension, diabetes mellitus, body mass index (BMI), waist circumference, HDL and trigliseride levels were evaluated. The TNM classification was used, with Ta tumor accepted as lower stage and T1 and T2 tumors as higher stage bladder cancers. Also, the pathological grading adopted by the 2004 World Health Organization grading system were applied. Non-invasive papillary urothelial neoplasms of low malignant potential were regarded as low grade. Results: Among the total of 509 patients analyzed in our study, there were 439 males (86.2%) and 70 females (13.8%). Metabolic syndrome was significantly associated with high histologic grade, and high pathologic stage (p<0.001). Conclusions: The patients with metabolic syndrome were found to have statistically significant higher T stage and grade of bladder cancer. Further studies with more patients are needed to confirm our study.